Oculis Holding AG
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Riad Sherif
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Bahnhofstrasse 7 Zug ZG Switzerland 6300
- IPO Date
- May 18, 2021
- CIK
- 0001953530
- Website
- oculis.com
- Similar Companies
- Business
- Oculis Holding AG (Nasdaq: OCS) is a global biopharmaceutical company focused on developing transformative eye therapies to address unmet medical needs in ophthalmology. The company offers a pipeline of investigational product candidates, including OCS-01, a topical eye drop formulation of dexamethasone for the treatment of diabetic macular edema; OCS-02, a topical eye drop formulation of meloxicam for the treatment of dry eye disease and post-operative inflammation and pain; OCS-05, a topical eye drop formulation of lanosterol for the treatment of presbyopia; and OCS-09, a biologic targeting neurotrophic keratitis, among others. These therapies leverage Oculis's proprietary soluble NSAID platform and other advanced delivery technologies to improve efficacy, safety, and patient compliance in anterior and posterior segment eye diseases. Oculis operates primarily in the biopharmaceutical industry, targeting patients with retinal, corneal, and inflammatory eye conditions through clinical-stage development and potential commercialization. Founded in 2018 and headquartered in Lausanne, Switzerland, with additional operations in the United States and Europe, the company maintains subsidiaries including Oculis Vision Sciences Inc. in the U.S. In recent developments, Oculis reported positive topline results from its Phase 3 DIAMOND Phase 3 trial of OCS-01 in May 2025, demonstrating statistically significant and clinically meaningful improvements in best-corrected visual acuity in patients with diabetic macular edema.[web:previous] The company also advanced OCS-02 into Phase 2 trials for dry eye disease and secured a strategic collaboration with a leading contract development and manufacturing organization in late 2024 to support scale-up for Phase 3 readiness. Additionally, Oculis completed a successful equity financing round in Q1 2025, raising approximately $100 million to fund pipeline progression and operational expansion into key markets. These milestones reflect Oculis's strategic shift toward late-stage clinical execution and preparation for regulatory submissions in major jurisdictions including the U.S. and Europe.[web:previous]
Company News
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Oculis (NASDAQ:OCS) Hits New 1-Year Low – Should You Sell?
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS
Oculis Announces Resignation of Lionel Carnot from Board of Directors
Oculis Announces Resignation of Lionel Carnot from Board of Directors
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026
Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $39.44
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses